Blood
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.
Steven Knapper, Laura W Dillon, Malavika Babu, Abin Thomas, Ian Thomas, Christopher S Hourigan, Georgia M Andrew, Richard James Dillon, Amanda Frances Gilkes, Nuria Marquez-Almuina, Sophie King, Nicholas McCarthy, Reem Bahr, Rasha W Al-Ali, Louisa Stone
Published: 202510.1182/blood.2025031006
Abstract
We compared daunorubicin/AraC plus fractionated gemtuzumab (DAGO2) with CPX-351 (CPX) (1:2 randomisation) in 439 patients ≥60yrs (median age 68yrs) without known adverse-risk cytogenetics entering the NCRI AML18 version2 trial (NCT02272478). Median f…
Preview only. Read the full abstract at the source